Ghassemi F, Sheibani S, Arjmand M, et al. - Researchers conducted this retrospective, non-randomized comparative case series to report the non-inferiority of new made iodine-125 ( ¹²⁵I) vs ruthenium-106 ( ¹⁰⁶Ru) episcleral plaque radiation. Between September 2013 and August 2017, the patients {n = 35; mean age was 47.3 years (range, 21–77 years; standard deviation [SD], 13.8 years)} treated with ¹²⁵I and ¹⁰⁶Ru episcleral plaques for choroidal melanoma at Farabi Hospital were compared in this series. Multivariate linear regression analysis demonstrated that the final diameter was only, independently and significantly, associated with the pretreatment diameter of the tumor. According to findings, ¹²⁵I plaque radiotherapy resulted in 100% local control rate by an average of 30-month follow-up and vision preservation in 33% of cases by an average of 2.5 years of follow-up. Patients treated with the ¹²⁵I plaques had no new complications which could preclude its acceptance. In terms of effectiveness and globe and vision saving, the ¹²⁵I plaques were comparable with ¹⁰⁶Ru plaques brachytherapy even superior in thickness control.